BR112023019301A2 - Formulações de vacina de coronavírus - Google Patents

Formulações de vacina de coronavírus

Info

Publication number
BR112023019301A2
BR112023019301A2 BR112023019301A BR112023019301A BR112023019301A2 BR 112023019301 A2 BR112023019301 A2 BR 112023019301A2 BR 112023019301 A BR112023019301 A BR 112023019301A BR 112023019301 A BR112023019301 A BR 112023019301A BR 112023019301 A2 BR112023019301 A2 BR 112023019301A2
Authority
BR
Brazil
Prior art keywords
vaccine formulations
nanoparticles
coronavirus vaccine
coronavirus
formulations
Prior art date
Application number
BR112023019301A
Other languages
English (en)
Inventor
Gale Smith
Jing-Hui Tian
J Massare Michael
Original Assignee
Novavax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novavax Inc filed Critical Novavax Inc
Publication of BR112023019301A2 publication Critical patent/BR112023019301A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

formulações de vacina de coronavírus. são reveladas aqui proteínas spike (s) de coronavírus e nanopartículas compreendendo as mesmas, que são apropriadas para uso em vacinas. as nanopartículas apresentam antígenos provenientes de patógenos circundados por e associados com um núcleo detergente resultando em estabilidade intensificada e uma boa imunogenicidade. dosagens, formulações e métodos para preparar as vacinas e as nanopartículas também são revelados.
BR112023019301A 2021-03-22 2022-03-18 Formulações de vacina de coronavírus BR112023019301A2 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163164487P 2021-03-22 2021-03-22
US202163176825P 2021-04-19 2021-04-19
US202163177059P 2021-04-20 2021-04-20
US202163195986P 2021-06-02 2021-06-02
US202163280395P 2021-11-17 2021-11-17
US202163290439P 2021-12-16 2021-12-16
US202163292196P 2021-12-21 2021-12-21
US202163293468P 2021-12-23 2021-12-23
PCT/US2022/020974 WO2022203963A1 (en) 2021-03-22 2022-03-18 Coronavirus vaccine formulations

Publications (1)

Publication Number Publication Date
BR112023019301A2 true BR112023019301A2 (pt) 2023-12-05

Family

ID=83396030

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023019301A BR112023019301A2 (pt) 2021-03-22 2022-03-18 Formulações de vacina de coronavírus

Country Status (11)

Country Link
US (1) US20220332765A1 (pt)
EP (1) EP4313143A1 (pt)
JP (1) JP2024511412A (pt)
KR (1) KR20230160349A (pt)
AU (1) AU2022245141A1 (pt)
BR (1) BR112023019301A2 (pt)
CA (1) CA3213221A1 (pt)
IL (1) IL306088A (pt)
MX (1) MX2023011163A (pt)
TW (1) TW202304955A (pt)
WO (1) WO2022203963A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202009206QA (en) * 2018-03-19 2020-10-29 Novavax Inc Multivalent influenza nanoparticle vaccines
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
WO2023196634A2 (en) 2022-04-08 2023-10-12 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
WO2024151583A2 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10953089B1 (en) * 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
US20210228707A1 (en) * 2020-01-28 2021-07-29 Modernatx, Inc. Coronavirus rna vaccines
CN116096732A (zh) * 2020-01-31 2023-05-09 贝斯以色列护理医疗中心有限公司 用于预防和治疗冠状病毒感染的组合物和方法-sars-cov-2疫苗

Also Published As

Publication number Publication date
MX2023011163A (es) 2024-02-27
TW202304955A (zh) 2023-02-01
EP4313143A1 (en) 2024-02-07
KR20230160349A (ko) 2023-11-23
AU2022245141A9 (en) 2024-02-22
JP2024511412A (ja) 2024-03-13
WO2022203963A1 (en) 2022-09-29
US20220332765A1 (en) 2022-10-20
AU2022245141A1 (en) 2023-10-05
CA3213221A1 (en) 2022-09-29
IL306088A (en) 2023-11-01

Similar Documents

Publication Publication Date Title
BR112023019301A2 (pt) Formulações de vacina de coronavírus
BR112018004242A2 (pt) composições de vacina que possuem estabilidade e imunogenicidade aumentadas
BR112022014830A2 (pt) Formulações de vacina para coronavírus
CY1121211T1 (el) Εμβολιο ιου ερπητα ζωστηρα
CY1118372T1 (el) Νεα μεθοδος και συνθεσεις
BR112018013387A2 (pt) vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit
BRPI1013780B8 (pt) Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
WO2007024941A3 (en) Polyvalent vaccine
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
TW200722101A (en) Novel composition
CO6260103A2 (es) Composiciones que comprenden antigenos neumococidos
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
PT2364724E (pt) Composição de vacina compreendendo um adjuvante de saponina
ATE527281T1 (de) Impfstoffe gegen aids umfassend cmv/r nucleinsäurekonstrukte
AR061894A1 (es) Vacunas para malaria
MX2024006589A (es) Formulaciones de vacunas contra el coronavirus.
MX2019007349A (es) Vacuna combinada para cerdos.
BRPI1007721B1 (pt) composição de vacina para uso na indução de uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolado de cdc-9 e cepa de rotavírus isolado de cdc-66
BR112013000394B8 (pt) Composição imunogênica, uso da mesma e método para preparar a referida composição
BR112015005056A2 (pt) vacinas de combinação com sorogrupo b meningococcus e d/t/p
WO2008148057A3 (en) Cationic lipids compositions and methods for enhancing immune responses to vaccines
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
BR112023021812A2 (pt) Composição vacinal adjuvantada e métodos
CY1112575T1 (el) Βελτιωμενα αδρανοποιημενα εμβολια fcv